32 results about "Cystine knot" patented technology

Nutraceutical and dietary supplement formulations for delivering bioavailable thiols to a host, comprising certain organosulfur radicals, such as the allyl mercapto radical, bound to larger molecules such as proteins, resulting in the formation in the host's body of various allium-related compounds such as allicin. The formulations are produced by treating an ingestible material comprising a cysteine-containing protein with a thiol, disulfide, mixed disulfide, thiosufinate or mixed thiosulfinate so as to cause thiol residues to become disulfide bonded to cysteines contained in the protein.

Vaccine displaying native antigenic loops of immunoglobulin E is critical for eliciting neutralizing anti-IgE antibodies. The embodiment of the invention enables the display of native antigenic IgE receptor-contacting loops as IgE B-cell vaccines via three steps of constraining methods. The loops of multiple antigenic B-cell epitopes can be molecularly grafted in, and conformationally constrained by the energy favorable flanking beta (b)-stands, i.e., the super b-strands identified in this invention. The constrained loops can be further stabilized in replacing a selective loop within the cystine knot peptide. These dual constrained antigenic loops are then integrated onto thermostable protein scaffolds, folded in the oxidative milieu that provides further conformational constraint and high yield.

Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against αIIbβ3 integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to αIIbβ3 integrin or to both αIIbβ3 and αVβ3 integrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for αIIbβ3 integrin.

This invention relates to a novel protein (INSP002), herein identified as a secreted protein that is a member of the Dan family of the cystine-knot fold cytokine superfamily and to the use of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

A protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain. Also described herein is an immunoconjugate containing the protein carrier with an antigen conjugated to multiple cysteine residues in the cysteine-rich domain, and an immune composition containing the immunoconjugate and an adjuvant, as well as their uses in eliciting immune responses.

The invention discloses a capsaicin liquid crystal nano spray preparation for promoting skin wound healing and a preparation method thereof. The capsaicin liquid crystal nano spray preparation is prepared from, by weight, 0.1-0.5% of capsaicin, 50-70% of a liquid crystal material, 5-10% of chitosan, 5-10% of a surfactant, 10-15% of a cosolvent and the balance water. The liquid crystal material isformed by mixing phosphatidyl glycerol and glyceryl dioleate in the weight ratio of 1:(1-3). The preparation method of the spray preparation comprises the steps that the capsaicin, the liquid crystalmaterial and the chitosan are dissolved and dispersed to form drug-loaded liquid crystal nanoparticles under the action of the cosolvent, the stability of the drug-loaded liquid crystal nanoparticlescan be greatly improved through the above operation, and the slow-release effect is obvious. The chitosan is combined with cysteine in the body to form a film on an affected part, the chitosan also has an antibacterial effect, the effects of isolating and protecting the affected part are achieved, and the action time of the medicine is prolonged, so that the local medicine concentration is obviously increased, the medicine takes effect easily, and wound healing is promoted.

Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin αvβ6. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in αvβ6-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin αvβ6 receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.

Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFβ superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.

The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation.

The invention a thrombolytic drug based on cobra venom PIIII type metalloproteinase which is obtained by separating and purifying venom of Chinese cobra or Naja cobra with a class name of Naja atra. The metalloproteinase is singe strand glycoprotein, structural analysis shows that the metalloproteinase has three structural domains, namely a metalloproteinase structural domain, a disintegrin structural domain and a cysteine-rich structural domain and belongs to PIIII type metalloproteinase with names of Atrase A and Atrase B. A sequence of the Atrase A is SEQ ID No.1, and a sequence of the Atrase B is SEQ ID No.2. Target protein and the thrombolytic drug can induce endogenous fibrinolytic enzyme activator tPA release so as to play a thrombolytic role, and the thrombolytic drug can be used for thrombolytic treatment of thrombotic diseases.

Provided are peptides, and pharmaceutical compositions and uses thereof. The peptides are as shown in the sequence listing, and are amino acid sequences having an analgesic effect, or pharmaceutically acceptable salts thereof. The two cysteine at the head end and the tail end of a peptide provided forms a ring. The pharmacophore (domain) having the analgesic effect in the GsMTx-4 polypeptide is determined by comparing the sequences of multiple polypeptides containing cysteine knots (ICK), such as GsMTx-4 and GsMTX-2, and by means of behavioral measurement on rat pain models.

The invention relates to a strain capable of producing L-arginine and a method for producing the L-arginine by the strain and belongs to the technical field of biological engineering. For the strain, Brevibacterium flavum ATCC 14067 is used as a starting strain; nitrosoguanidine is adopted to carry out mutagenesis step by step; mutant strains with histidine and succinic acid auxotrophic strains are screened out so as to cut off a competitive metabolic pathway; and mutant strains (His-, Suc-, D-Argr, SMCr) with resistances of arginine structural analogs and cysteine structural analogs are screened out. The strain is named as Brevibacterium flavum HX1009, is preserved in the China general microbiological culture collection center, has the preservation number of CGMCC No.4464 and has the genetic characters of histidine auxotroph His-, succinic acid auxotroph Suc-, D-arginine resistance D-Argr and S-methyl cysteine resistance SMCr for improving the yield of the L-arginine. Under the optimized condition, the L-arginine is produced by fermentation on a fermentation tank with the volume of 5L to 5M3 and the arginine production level achieves 50 to 70g / L.

Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin αvβ6. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in αvβ6-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin αvβ6 receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.

The present invention relates to a method for preparing hypoallergenic whey proteins by cysteine-bound transglutaminase modification and belongs to the technical field of dairy product processing. Theobject of the method is as follows: in order to reduce allergenicity of whey proteins, the reducing property of the cysteine is utilized to open disulfide bonds in protein molecules, so as to bind the transglutaminase, so that whey protein cross-linking is further promoted, thereby developing a modification method that effectively reduces the allergenicity of the whey proteins.

Compositions and methods based on mutant Cystine Knot Growth Factors (CKGFs) comprising amino acid substitutions relative to the wild type hormone / growth factor. Mutated glycoprotein hormones, including thyroid stimulating hormone (TSH) and chorionic gonadotropin (CG) are disclosed as exemplary mutant CKGFs. Mutant TSH heterodimers and hCH heterodimers possessed modified bioactivities, including superagonist activity. Accordingly, the present invention provides methods for using mutant CKGFs, CKGF analogs, fragments, and derivatives thereof for treating or preventing diseases. Pharmaceutical and diagnostic compositions, methods of using mutant TSH heterodimers and TSH analogs with utility for treatment and prevention of metabolic and reproductive diseases are also provided.